

Bryon D Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1156744/publications.pdf>

Version: 2024-02-01

58
papers

1,634
citations

471509

17
h-index

330143

37
g-index

59
all docs

59
docs citations

59
times ranked

2835
citing authors

#	ARTICLE	IF	CITATIONS
1	Unrelated donor T cell and B cell-depleted HSCT for the treatment of pediatric acute leukemia. Blood Advances, 2022, 6, 1175-1185.	5.2	9
2	Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone. Advanced Science, 2022, 9, e2101267.	11.2	17
3	Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncology, 2022, 8, 773.	7.1	11
4	Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. Communications Medicine, 2022, 2, .	4.2	5
5	A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2022, 40, TPS7070-TPS7070.	1.6	2
6	Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 683-685.	2.4	7
7	STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 41-58.	4.5	35
8	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. Journal of Cancer Prevention, 2021, 26, 71-82.	2.0	4
9	PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. Haematologica, 2021, 106, 2788-2790.	3.5	4
10	Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. iScience, 2021, 24, 102653.	4.1	18
11	Abstract 1618: Inhibition of lung tumorigenesis by a novel small molecule CA170 targeting the immune checkpoint protein VISTA. , 2021, , .		0
12	Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA. Communications Biology, 2021, 4, 906.	4.4	12
13	Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?. Cytotherapy, 2021, 23, 985-990.	0.7	12
14	Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT) Tj ETQq0 0 0. BT /Overlock 10 T		
15	Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System. Blood, 2021, 138, 476-476.	1.4	0
16	A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma. Blood, 2021, 138, 4401-4401.	1.4	5
17	Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2. Blood, 2021, 138, 1728-1728.	1.4	0
18	Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose. Blood, 2021, 138, 3883-3883.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 95-95.	1.4	2
20	Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. <i>Journal of Cancer Prevention</i> , 2021, 26, 309-317.	2.0	1
21	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nature Medicine</i> , 2020, 26, 1569-1575.	30.7	266
22	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2011-2017.	2.0	11
23	Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. <i>Blood Advances</i> , 2020, 4, 2119-2122.	5.2	32
24	Treatment-Emergent Tumor Lysis Syndrome With PI3K $\hat{\imath}$ 3 Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. <i>JCO Oncology Practice</i> , 2020, 16, 613-614.	2.9	1
25	Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy. <i>Blood</i> , 2020, 136, 33-34.	1.4	5
26	Phase II trial using haploidentical hematopoietic cell transplantation (HCT) followed by donor natural killer (NK) cell infusion and sirolimus maintenance for patients with high-risk solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23551-e23551.	1.6	5
27	Successful Manufacturing of CAR T-Cells with Small Volume Peripheral Blood from Healthy Donors Using the Clinimacs Prodigy Device. <i>Blood</i> , 2020, 136, 27-28.	1.4	1
28	Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial. <i>Blood</i> , 2020, 136, 22-22.	1.4	2
29	Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449). <i>Blood</i> , 2020, 136, 2-4.	1.4	1
30	Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359). <i>Blood</i> , 2020, 136, 20-21.	1.4	0
31	Potential of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator. <i>EBioMedicine</i> , 2019, 49, 72-81.	6.1	33
32	An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. <i>Journal of Clinical Apheresis</i> , 2019, 34, 686-691.	1.3	3
33	Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 146.	2.8	123
34	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1492-1497.	2.0	23
35	A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 680-689.	2.5	2
36	Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4465-4465.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2019, 37, 2510-2510.	1.6	35
38	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft- <i>versus</i> -host disease: low incidence of lower gastrointestinal tract disease. Haematologica, 2018, 103, 717-727.	3.5	38
39	Frontline Science: PECAM-1 (CD31) expression in na ^ï ve and memory, but not acutely activated, CD8+ T cells. Journal of Leukocyte Biology, 2018, 104, 883-893.	3.3	24
40	Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer, 2018, 18, 335.	2.6	271
41	A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma. Blood, 2018, 132, 4193-4193.	1.4	27
42	Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL. Blood, 2018, 132, 4553-4553.	1.4	5
43	Diacylglycerol Kinase $\hat{\eta}$ (DGK $\hat{\eta}$) and Casitas b-Lineage Proto-Oncogene \hat{b} Deficient Mice Have Similar Functional Outcomes in T Cells but DGK $\hat{\eta}$ -Deficient Mice Have Increased T Cell Activation and Tumor Clearance. ImmunoHorizons, 2018, 2, 107-118.	1.8	13
44	Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 740-745.	7.1	25
45	T Cells Deficient in Diacylglycerol Kinase $\hat{\eta}$ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia. Cancer Research, 2017, 77, 5676-5686.	0.9	17
46	Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice. , 2017, 5, 51.		23
47	Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer. Frontiers in Cell and Developmental Biology, 2016, 4, 108.	3.7	45
48	Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. Cancer Research, 2016, 76, 3904-3915.	0.9	159
49	p38 $\hat{\beta}$ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion. Stem Cells, 2015, 33, 2738-2747.	3.2	35
50	Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma. , 2015, 3, 24.		11
51	Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. , 2015, 3, 2.		93
52	Exciting new murine model of cGVHD. Blood, 2012, 119, 1331-1332.	1.4	1
53	Robert Truitt Tribute. Biology of Blood and Marrow Transplantation, 2010, 16, 143-144.	2.0	0
54	Alloantigen-specific regulatory T cells. Blood, 2004, 103, 4000-4000.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. <i>Cellular Immunology</i> , 2003, 222, 15-26.	3.0	28
56	CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 525-535.	2.0	102
57	Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 581-587.	2.0	1
58	The Graft-Versus-Leukemia Effect of Post-transplant Donor Leukocyte Infusion. <i>Leukemia and Lymphoma</i> , 1996, 23, 1-9.	1.3	15